CELU Stock Forecast: Celularity, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Celularity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (10): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CELU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CELU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 13 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2025 | WBB Securities | Upgrade | Buy | $6.00 |
| 18 Aug 2025 | WBB Securities | Initiates | Speculative Buy | — |
| 30 Jan 2023 | HC Wainwright & Co. | Maintains | Buy | $15 → $2.50 |
| 30 Jan 2023 | Morgan Stanley | Downgrade | Underweight | $5.00 → $1.00 |
| 22 Dec 2022 | Oppenheimer | Downgrade | Perform | — |
| 12 Sept 2022 | Morgan Stanley | Maintains | Equal-Weight | $8.00 → $5.00 |
| 25 Aug 2022 | Alliance Global Partners | Initiates | Buy | $15 |
| 23 Aug 2022 | Truist Securities | Maintains | Hold | $10 → $6.00 |
| 22 June 2022 | HC Wainwright & Co. | Initiates | Buy | — |
| 6 Apr 2022 | Truist Securities | Downgrade | Hold | — |
| 28 Jan 2022 | Oppenheimer | Initiates | Outperform | — |
| 24 Nov 2021 | Morgan Stanley | Initiates | Equal-Weight | — |
| 19 Oct 2021 | Truist Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
CELU appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CELU vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Celularity, Inc. returned −73.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CELU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.8×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- −79.7%
- Operating margin
- —
- Net margin
- —
Higher than 2% of US stocks
- Return on equity
- —
- Return on assets
- −27.4%
- Dividend yield
- —
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Celularity, Inc. has a market value of $15.0M and an enterprise value of $86.2M.
Revenue in the twelve months to 31 Dec 2025: $26.6M. The latest quarter shrank 77.4% year on year.
Net income over the same four quarters: −$91.7M, a −345.4% net margin.
Free cash flow in the twelve months to 31 Dec 2025: −$13.3M, after $0.0 of capital spending.
Celularity, Inc. employs 115 people — $231K of revenue per employee.
Data provided by Twelve Data
CELU and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CELU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Celularity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CELU
How does Ticker Nerd's model rank CELU?
As at 21 Nov 2026, Celularity, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).
What is the CELU stock forecast for 2030?
No analyst covering Celularity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELU are extrapolating price history, which says nothing about the business.
How has CELU stock performed over the past year?
Celularity, Inc. returned -73.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Celularity, Inc. do?
Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking.
About Celularity, Inc.
Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The Cell Therapy segment develops off-the-shelf, cryopreserved allogeneic cell therapies, including programs based on mesenchymal-like adherent stromal cells, natural killer cells, and engineered T-cells for oncology, immune, infectious, and age-related diseases. The Degenerative Disease segment supports products used in surgical and wound care markets, while BioBanking provides storage services for stem cells from umbilical cords and placentas. Headquartered in Florham Park, New Jersey, Celularity occupies a niche within biotechnology that combines regenerative medicine research with commercial biobanking and biomaterials services.
CEO Dr. Robert Joseph Hariri M.D., Ph.D. · 115 employees · United States · https://www.celularity.com